Closeout of the HALT-PKD trials.

[1]  Galit Shmueli,et al.  Fundamentals of Clinical Trials, 4th edition , 2012 .

[2]  Douglas Landsittel,et al.  Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[3]  B. Barnes.  The Coronary Drug Project , 1972 .

[4]  R McBride,et al.  Interim reports, participant closeout, and study archives. , 1995, Controlled clinical trials.

[5]  Tony Tse,et al.  Reporting "basic results" in ClinicalTrials.gov. , 2009, Chest.

[6]  W. Krol.  Closing down the study , 1983 .

[7]  J. Ellenberg,et al.  The closeout process for a clinical trial terminated early for lagging enrollment and inadequate follow-up. , 2001, Controlled clinical trials.

[8]  R. Schrier,et al.  Blood pressure in early autosomal dominant polycystic kidney disease. , 2015, The New England journal of medicine.

[9]  N. Rege,et al.  ICH Harmonised Tripartite Guideline: guideline for good clinical practice. , 2001, Journal of postgraduate medicine.

[10]  Gary Gensler,et al.  Central site monitoring: Results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection , 2014, Clinical trials.

[11]  Taghrid Obied,et al.  Oversight of clinical investigations- A risk based approach to monitoring , 2014 .

[12]  F. Miller,et al.  Disclosing individual results of clinical research: implications of respect for participants. , 2005, JAMA.

[13]  Tomasz Burzykowski,et al.  A statistical approach to central monitoring of data quality in clinical trials , 2012, Clinical trials.

[14]  P. Canner.  Coronary drug project. , 2014, JAMA.

[15]  B. Davis,et al.  Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2001, Controlled clinical trials.

[16]  Diego R. Martín,et al.  Analysis of baseline parameters in the HALT polycystic kidney disease trials. , 2012, Kidney international.

[17]  Jang Hwan Kim.  Book Review: Fundamentals of Clinical Trials. 4th ed. , 2013, International Neurourology Journal.

[18]  R. L. Bell,et al.  Termination of clinical trials: the beta-blocker heart attack trial and the hypertension detection and follow-up program experience. , 1985, Controlled clinical trials.

[19]  D. DeMets,et al.  Fundamentals of Clinical Trials , 1982 .

[20]  K P Offord,et al.  Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980. , 1983, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  A. Gaw,et al.  Closing out a large clinical trial: lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) , 2004, Clinical trials.

[22]  A. Gaw,et al.  Unblinding of trial participants to their treatment allocation: lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) , 2005, Clinical trials.

[23]  W. Krol.  The Coronary Drug Project. Closing down the study. , 1983, Controlled clinical trials.

[24]  D. Grady,et al.  Planning for closeout--from Day One. , 2008, Contemporary clinical trials.

[25]  J. Miller,et al.  The HALT polycystic kidney disease trials: design and implementation. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[26]  Kaleab Z. Abebe,et al.  Blood pressure in early autosomal dominant polycystic kidney disease. , 2014, The New England journal of medicine.

[27]  Kaleab Z. Abebe,et al.  Angiotensin blockade in late autosomal dominant polycystic kidney disease. , 2014, The New England journal of medicine.

[28]  James Topping,et al.  Compliance with results reporting at ClinicalTrials.gov. , 2015, The New England journal of medicine.